Chances Upped Supreme Court Hears Amgen/Sandoz Biosimilars Suit

 
• By Donna Young
  
Generate a summary of this article
Listen to this article
Beta

While an invitation for the top US government litigator to weigh in on Amgen Inc. v. Sandoz Inc. has prolonged the Supreme Court's decision on whether it will take up the case – creating a certain amount of limbo for the biosimilars marketplace – the request demonstrates the justices appear to be taking the matter seriously, upping the chances they may hear oral arguments potentially next spring.

The US Supreme Court's June 20 invitation to the solicitor general (SG) – the federal government's top litigator – to weigh in on Amgen Inc.'s and Sandoz Inc.'s legal battle over the interpretation of the law that gave the FDA the power to approve biosimilars, the Biologics Price Competition and Innovation Act (BPCIA), shows how seriously the justices are taking the case, according to lawyers who are closely watching the lawsuit.

The outcome of whether the court takes up Amgen v. Sandoz, which was spurred by the circumstances surrounding the marketing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.